Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443527 | 0.95 | SLC6A3 (0.49) | SLC6A3SLC6A4LMNASTING1ACHE | |
| SCHEMBL6352266 | 0.92 | SLC6A3 (0.47) | SLC6A3SLC6A4LMNAACHEALDH1A1 | |
| SCHEMBL9486496 | 0.84 | SLC6A3 (0.42) | SLC6A3SLC6A4LMNAACHEALDH1A1 | |
| SCHEMBL11041015 | 0.82 | GAA (0.44) | SLC6A3SLC6A4LMNAACHEALDH1A1 | |
| SCHEMBL21820651 | 0.76 | SLC6A4 (0.37) | SLC6A3SLC6A4LMNAALDH1A1GAA | |
| SCHEMBL8239013 | 0.75 | SLC6A3 (0.64) | SLC6A3SLC6A4LMNA | |
| SCHEMBL9819527 | 0.75 | SLC6A3 (0.47) | SLC6A3SLC6A4LMNAALDH1A1GAA | |
| SCHEMBL14902438 | 0.74 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL28409092 | 0.73 | PDE2A (0.37) | SLC6A3SLC6A4LMNAALDH1A1MEN1 | |
| SCHEMBL8804172 | 0.73 | SLC6A3 (0.57) | SLC6A3SLC6A4LMNAALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-9920035-B2 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150336933-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| CN-101394847-A | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC (US) | 2009-03-25 | — | — | CN | disclosed |
| EP-1976513-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | Sepracor, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | SCNN1B, SCNN1A, TRPM5 | SLC6A3 1358/4885SLC6A4 512/4885LMNA 495/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885LMNA 2549/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885LMNA 2549/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885LMNA 2549/4885 |
| US-20150336933-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | SCNN1B, SCNN1A, TRPM5 | SLC6A3 1358/4885SLC6A4 512/4885LMNA 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.